First Quarter 2025 Earnings May 6, 2025 3 1 Safe Harbor Statement Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words "may," "will," "expect," "believe," "anticipate," "plan," "estimate," "project," "assume," "guide," "target," "forecast," "see," "seek," "can," "should," "could," "would," "intend," "predict," "pote ...

Business Overview - VTEX is a SaaS digital commerce platform for enterprise brands and retailers [8, 12] - 88% of VTEX's ARR comes from enterprise customers, each generating at least $25K ARR, with an average of $131K in ARR as of FY 2024 [12] - VTEX's platform processed $18.2 billion in GMV B2C in FY 2024 [14] - VTEX has 3400 customers and 2400 active online stores across 43 countries as of FY 2024 [15] Financial Performance - VTEX achieved $226.7 million in revenue in FY 2024 [15] - The company's non-GAAP subscription gross margin was 78.2% in FY 2024 [15] - Non-GAAP income from operations margin increased from 19.1% in 4Q23 to 20.1% in 4Q24 [78] - VTEX's subscription revenue grew by 20.2% FX Neutral in 2024, reaching $228.8 million [94] Growth and Strategy - VTEX has a LTV/CAC ratio above 6x [48] - VTEX's Top 100 Customers are growing, with ARR increasing from $23.9 million in 2017 to $98.7 million in 2024, a 29% FXN CAGR [55, 57]

Q1 2025 Financial Performance - Net revenue reached $1.77 billion, a 19% year-over-year increase[12, 14] - Adjusted EBITDA was $168 million, up 23% year-over-year[12, 14] - Adjusted EPS increased to $0.63, a 34% year-over-year rise[12, 14] - Cash used by operating activities was $65 million, primarily due to increased accounts receivable and early payments to suppliers[13] Segment Performance - Products & Solutions (P&S) revenue grew by 5% year-over-year to $649 million[14, 16] - P&S Adjusted EBITDA increased by 13% year-over-year to $158 million[14, 16] - ADI Global Distribution revenue increased by 29% year-over-year to $1.121 billion[14, 16] - ADI Adjusted EBITDA increased by 24% year-over-year to $72 million[14, 16] Financial Outlook for 2025 - The company projects total net revenue between $7.285 billion and $7.485 billion for 2025[27] - Adjusted EBITDA is expected to be in the range of $725 million to $805 million for 2025[27]

Financial Performance - Since launch, OJEMDA net product revenue reached $87.7 million[10, 14] - In Q1 2025, OJEMDA net product revenue was $30.5 million[10, 14, 19] - Q1 2025 saw a $3 million (+11%) increase in U S net product revenue compared to Q4 2024[14, 19] - Total revenue for Q1 2025 was $30.8 million[29] - The company holds a strong financial position with $473 million in cash[10, 29] - Net loss for the company was ($360) million[29] Commercial Performance - Cumulative prescriptions since launch totaled 2,571[14, 21] - Prescription growth in Q1 2025 was driven by new patient starts and continued therapy among on-label patients[21] Market Opportunity - Priority 1 centers manage approximately 4,000 estimated patients[24] - Priority 2 centers manage approximately 5,000 estimated patients[24] - Priority 3 centers manage approximately 4,000 estimated patients[24]

First Quarter 2025 Earnings Release LUCID GROUP, INC. May 6, 2025 FIRST QUARTER 2025 EARNINGS RELEASE Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "shall," "expect," "anticipate," "believe," "seek," "target," "continue ...

Strategic Goals - Finance of America aims to mainstream home equity for retirement by positioning reverse mortgages alongside common financing options[4] - The company intends to break the adoption barrier and increase customer numbers by elevating its brand and offering a customer-centric experience[4] - Finance of America is targeting homeowners 55+ to leverage their home equity for retirement[13] Key Initiatives - Finance of America is modernizing messaging, developing progressive digital experiences, and providing unparalleled customer care to attract a new kind of borrower[5] - The company launched the "A Better Way with FOA" campaign[6] - Finance of America is using performance ads to bring reverse mortgages from the fringe to the mainstream[8] - Finance of America is setting a new standard as the voice of the category through consumer education[11] Brand Positioning - The "Better Way" brand platform positions Finance of America as a trusted partner[13]

Q1 2025 Earnings May 6, 2025 Forward-looking Statements / Legal Disclaimer $4.10 BILLION Management of Energy Transfer LP (ET) will provide this presentation in conjunction with ET's 1st quarter 2025 earnings conference call. On the call, members of management may make statements about future events, outlook and expectations related to Sunoco LP (SUN), USA Compression Partners, LP (USAC), and ET (collectively, the Partnerships), and their subsidiaries and this presentation may contain statements about futur ...

coupang Q1 2025 Financial Results May 6, 2025 Disclaimer Forward-Looking Statements This presentation may contain statements that may be deemed to be "forward-kooking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (together, the "Act") that are intended to enjoy the protection of the safe harbor for for ward looking statements provided by the Act ...

Financial Performance - Q1 2025 net product sales grew to $43.6 million, a 68% increase compared to Q1 2024[18, 92] - TAVALISSE net product sales in Q1 2025 were $28.5 million, a 35% increase compared to Q1 2024[20] - GAVRETO net product sales in Q1 2025 were $9.0 million[22] - REZLIDHIA net product sales in Q1 2025 were $6.1 million[22] - Collaboration revenues for Q1 2025 totaled $9.8 million[92] - Rigel anticipates 2025 total revenue of approximately $200 million to $210 million[96] - The company projects net product sales of approximately $185 million to $192 million for 2025, representing a 28% to 32% year-over-year growth[97, 98] Clinical Development Programs - Rigel is evaluating R289, a dual IRAK1/4 inhibitor, in a Phase 1b study for relapsed/refractory lower-risk MDS[13] - The company plans to initiate a Phase 2 study of olutasidenib in recurrent glioma[13] - Preliminary data from the R289 Phase 1b study in relapsed/refractory lower-risk MDS showed that at 500 & 750 mg QD doses, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients[59] Strategic Initiatives - Rigel is focused on identifying and in-licensing new late-stage assets that leverage current capabilities and capacity[10] - The company expanded its relationship with Kissei to include REZLIDHIA in Japan, the Republic of Korea, and Taiwan and entered into a relationship with Dr Reddy's in Latin America and other territories[29]

Financial Performance - The company reported a GAAP net loss of $0.29 per share[7] - Earnings Available for Distribution (EAD) was $0.17 per share[7] - The book value per common share decreased by 6.3% to $3.58, net of the quarterly dividend[8] - A dividend of $0.15 per share was declared and paid[8] - The company experienced a 2.4% total quarterly economic loss[8] Portfolio Metrics - The company's leverage ratio for the aggregate portfolio was 5.2x[8] - The net interest spread for RMBS was 3.6%[8] - The weighted average Constant Prepayment Rate (CPR) for RMBS was 5.8%[7] - The net CPR for Mortgage Servicing Rights (MSRs) was 4.1%[7] Asset Composition - As of March 31, 2025, 76% of the asset investment composition (excluding cash) was in 30 Year RMBS and 24% was in MSRs[15]